CND-319

N/A

Report date: 2026/03/19 17:11:49

Base Information

Drug NameCND-319

Drug Alias NameCND-319

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Trispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionCD3 T-cell engagersAnti-CD19Anti-CD20

TargetsT cell surface glycoprotein CD3B-lymphocyte antigen CD19B-lymphocyte antigen CD20

Therapy Area/IndicationsAutoimmune Diseases

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesCandid Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesCandid Therapeutics Inc

Inactive CompaniesN/A

Active IndicationsAutoimmune Diseases

Inactive IndicationsN/A

Other Information

ATC CodeN/A